secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2024-07-10T23:59:59+00:00
Accession:  0001213900-24-060537
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.01, 2.03, 5.03, 5.07, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Capital shareholders approve extension to Apr 2025; 3.8M shares redeemed for ~$43.4M
--------------------------------------------------------------------------------

- Shareholders approved extension of business combination deadline from July 11, 2024 to April 11, 2025 via monthly extensions.
- 3,785,992 public shares redeemed at ~$11.47 per share, removing ~$43.4 million from trust account; only 751,837 public shares remain.
- Sponsor issued a convertible promissory note of up to $180,000 to fund extension deposits; initial $15,063.74 deposited for one-month extension.
- Note is convertible into Class A ordinary shares at $10.00 per share upon business combination; no interest accrues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024060537/0001213900-24-060537-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000121390024060537/ea0209176-8k425_denali.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-060537

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer